All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are constantly updated:
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Corelink, Fist Assist Devices, Onkos Surgical, Phase Scientific.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, Aptar, Avania, Garwood, Icometrix, Imarc, Integrum, Mirador, Prognos, Sorrento Therapeutics, Thermo Fisher Scientific, Voluntis.
While biopharma deals are very much in line with the early pandemic months of 2020, mergers and acquisitions are telling a different story – one in which values are down by 76%. As of June 22, BioWorld has recorded 956 deals, including licensings, collaborations and joint ventures, valued at $80.2 billion in 2021, as well as 59 completed M&As worth $29.1 billion. In comparison with the same timeframe in 2020, the volume of both deals and M&As is down slightly by about 10 deals each, but the lack of high-value M&As, or mega-mergers worth more than $10 billion, has placed 2021 far behind last year. Deal values, however, are up by 4%.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anna, Augment, Big Cypress, Bioaxone, Cantex, Cybin, Fujitsu, Gyroscope, Iksuda, Legochem, Moderna, SAB, TFF, Vtv.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Anavex, Cytodyn, Cytomx, Innovent, Medicinova, Moleculin, Oyster Point, Redhill, Spruce, Tarsus, Theravance.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aiforia, Alibaba Health, Anatech, Avacta Group, Berry Oncology, Calibre Scientific, Cancer Diagnostics, Efferent Health, Epredia, Madison Core Laboratories, Paige, Parvizi Surgical Innovation, Predictive Health Diagnostics Company, Raysearch, SHL Telemedicine, VNA Care.
Shares of Vir Biotechnology Inc. (NASDAQ:VIR) and Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) each rose modestly on June 21 as both delivered positive updates on their COVID-19 programs. Vir and its partner, Glaxosmithkline plc, shared final clinical data confirming the efficacy of their monoclonal antibody therapy, sotrovimab, following an FDA emergency use authorization for the therapy last month. Cumberland announced five case studies in which its antibiotic, Vibativ (telavancin), successfully treated hospital-acquired and ventilator-associated bacterial pneumonia in COVID-19 patients.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Merck, Orphazyme, Sanofi.
RSS
